<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03997279</url>
  </required_header>
  <id_info>
    <org_study_id>AB-2019-4</org_study_id>
    <nct_id>NCT03997279</nct_id>
  </id_info>
  <brief_title>Assesment of the Efficiency and Safety Helicobacter Pylori Therapy With or Without Saccharomyces Boulardii</brief_title>
  <official_title>Double-blind, Placebo-controlled, Randomized Study for Assesment of the Efficiency and Safety Quadruple Therapy for Helicobacter Pylori Infection With or Without the Addition of Saccharomyces Boulardi Probiotic</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Clinical Centre of Serbia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Clinical Centre of Serbia</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study assesses the effect of quadruple therapy for H. pylori, with the addition of
      probiotics Saccharomyces boulardii. In addition, he assesses whether this combination reduces
      the frequency of adverse effects of eradication therapy, and whether it affects the
      compliance.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Standard triple therapy for H. pylori infection proved to be insufficiently effective,
      primarily due to antibiotics resistance.Therefore, the latest Maastricht consensus suggests
      using bismuth-quadruple or non-bismuth-quadruple therapy, in regions with high clarithromycin
      resistance. The addition of probiotics with eradication therapy has never become a standard
      treatment. However, the Maastricht consensus suggest that the addition of probiotics could
      increase the effectiveness of quadruple therapy.

      The study was designed as a prospective, double-blind, randomized, case-control intervention
      study.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 2019</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Result of urea breath test (Eradication of H.pylori)</measure>
    <time_frame>baseline to 8 weeks after the introduction of the therapy</time_frame>
    <description>Test remains positive (Eradication of H.pylori unsuccessful) or test becomes negative (eradication of H.pylori successful)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Side effects of eradication therapy</measure>
    <time_frame>baseline to 8 weeks after the introduction of the therapy</time_frame>
    <description>Number and severity of adverse events of standard eradication therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compliance of eradication therapy</measure>
    <time_frame>baseline to 8 weeks after the introduction of the therapy</time_frame>
    <description>Patient successfully completed prescribed therapy</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Helicobacter Pylori Infection</condition>
  <arm_group>
    <arm_group_label>S.boulardi</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Quadruple eradication therapy with S. boulardi</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Quadruple eradication therapy without S. boulardi</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saccharomyces boulardii</intervention_name>
    <description>Rabeprazole 20 mg 2x1, for 14 days, followed by 1x1 for 14 days, Amoxicillin 1000 mg 2x1, for 14 days, Clarithromycin 500 mg 2x1, for 14 days, Metronidazole 500 mg 2x1, for 14 days, Saccharomyces boulardi 500 mg 1x1, for 3 week</description>
    <arm_group_label>S.boulardi</arm_group_label>
    <other_name>Rabeprazole</other_name>
    <other_name>Amoxicillin</other_name>
    <other_name>Clarithromycin</other_name>
    <other_name>Metronidazole</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Rabeprazole 20 mg 2x1, for 14 days, followed by 1x1 for 14 days, Amoxicillin 1000 mg 2x1, for 14 days, Clarithromycin 500 mg 2x1, for 14 days, Metronidazole 500 mg 2x1, for 14 days, Placebo 1x1, for 3 week</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Rabeprazole</other_name>
    <other_name>Amoxicillin</other_name>
    <other_name>Clarithromycin</other_name>
    <other_name>Metronidazole</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Dyspepsia

          -  Patients not treated for H. Pylori

          -  Age of 18-50 years

          -  Positive urea breath test

        Exclusion Criteria:

          -  Alarm symptoms (anemia, persistent vomiting, hematemesis, dysphagia, significant
             weight loss, palpable mass in abdomen)

          -  Gastric cancer

          -  Immunosuppressive therapy

          -  Use of acetylsalicylic acid

          -  Severe renal failure

          -  Severe liver failure

          -  Immunodeficiency

          -  Proven malignant disease

          -  Penicillin allergy

          -  Allergy to any component of dietary supplement (Saccharomyces boulardii and Vitamin D)

          -  Chronic alcoholism

          -  Pregnancy

          -  Lactation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Miodrag Krstic, MD, PhD</last_name>
    <phone>+381113615575</phone>
    <email>krstic.miodrag61@gmail.com</email>
  </overall_contact>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>June 12, 2019</study_first_submitted>
  <study_first_submitted_qc>June 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 25, 2019</study_first_posted>
  <last_update_submitted>June 21, 2019</last_update_submitted>
  <last_update_submitted_qc>June 21, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 25, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Clinical Centre of Serbia</investigator_affiliation>
    <investigator_full_name>Miodrag Krstic</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <keyword>Helicobacter Pylori</keyword>
  <keyword>Saccharomyces boulardi</keyword>
  <keyword>Eradication therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Helicobacter Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amoxicillin</mesh_term>
    <mesh_term>Metronidazole</mesh_term>
    <mesh_term>Clarithromycin</mesh_term>
    <mesh_term>Rabeprazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

